肺癌新辅助化疗后淋巴结病理缓解的预后评估
本研究纳入75例接受新辅助化疗并完成手术切除的NSCLC患者,由两名对治疗与结局不知情的病理医师回顾性评估原发灶与受累淋巴结的病理缓解程度。结果显示淋巴结主要病理缓解(LN-MPR)单独即可显著预测长期总生存,LN-MPR联合原发灶MPR(PT-MPR)可将患者分为三个预后组(p = 0.001)。
要点
- LN-MPR单独即可显著预测新辅助化疗后NSCLC患者的总生存。
- LN-MPR联合PT-MPR可将患者分层为三个预后组(p = 0.001)。
- 淋巴结病理缓解评估或可补充原发灶MPR用于预后判断。
核心结论
- 淋巴结主要病理缓解(LN-MPR)单独即是接受新辅助化疗的NSCLC患者总生存的可靠预测指标。
- LN-MPR与PT-MPR联合与结局相关性良好,可用于该人群的预后预测。
研究设计与样本
- 回顾性研究,纳入75例接受新辅助化疗并完成手术切除的NSCLC患者。
- 组织标本由两名对患者治疗与结局不知情的病理医师评估原发灶及受累淋巴结的病理缓解程度。
- 采用Kaplan-Meier法与Cox回归模型评估LN-MPR单独或联合PT-MPR对总生存(OS)的预后价值。
主要发现
- LN-MPR对接受新辅助化疗后的长期OS具有显著预测作用。
- PT-MPR与LN-MPR联合与结局显著相关,并可将患者分层为三个预后组(p = 0.001)。
关键数值与推荐
- MPR定义为残留存活肿瘤小于或等于10%,目前作为可切除NSCLC新辅助化疗后生存的替代终点。
临床怎么用
- 在评估新辅助化疗后NSCLC手术标本时,除原发灶病理缓解外,应同时评估受累淋巴结的病理缓解程度。
- 可结合LN-MPR与PT-MPR进行预后分层,辅助识别高危患者。
局限性
- 回顾性研究,样本量为75例,结论需更大样本验证。
- 原文摘要未报告随访时间、各组具体生存数值及多因素分析细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Major pathologic response (MPR), defined as residual viable tumor of less than or equal to 10%, currently serves as a surrogate end point for survival for patients with resectable NSCLC after neoadjuvant chemotherapy. However, the significance of pathologic response in lymph nodes harboring metastatic tumors in such patients remains uncertain. Therefore, we studied the effect of neoadjuvant chemotherapy on resected positive lymph nodes and determined if the degree of pathologic response in the lymph nodes alone (LN-MPR) or in combination with that of the primary tumor (PT-MPR) was able to predict the outcome. METHODS: A total of 75 patients with NSCLC who underwent neoadjuvant chemotherapy and completed surgical resection were included in this study. Tissue specimens were retrospectively evaluated by two pathologists blinded to the patients' treatments and outcomes. Specimens were reviewed for the degree of pathologic response in the primary tumor and in any involved lymph nodes. The prognostic performance of LN-MPR alone or in combination with PT-MPR with respect to overall survival (OS) was evaluated using the Kaplan-Meier method and Cox regression model. RESULTS: LN-MPR was significantly predictive of long-term OS after neoadjuvant chemotherapy. A combination of PT-MPR with LN-MPR was significantly associated with outcome and allowed stratification of patients into three prognostic groups (p = 0.001). CONCLUSIONS: LN-MPR in isolation is a reliable predictor of OS in patients with NSCLC receiving neoadjuvant chemotherapy. A combination of LN-MPR with PT-MPR seems to correlate well with the outcome and can be used to predict prognosis in this patient population.
引用
- Pataer A, Weissferdt A, Vaporciyan AA, et al. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. J Thorac Oncol. 2021. PMID: 33857666. doi:10.1016/j.jtho.2021.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。